In the Netherlands, applicants have to pay a fee for the granting of government licenses, independent of the decision made regarding authorisation. This therefore also applies to applications for and registrations of marketing authorisations for medicinal products.

The pharmaceutical industry pays a fixed annual fee for each medicinal product authorised. This forms the basis of the MEB’s income. In addition, the pharmaceutical industry pays a fixed fee for new applications for the evaluation of medicinal products. These fees are sufficient to enable the MEB to perform its work cost-effectively. 

The fees are determined by the Minister of Health, Welfare and Sports and ratified by the House of Representatives. The fees for veterinary medicines are determined by the Ministry of Agriculture, Natuur en Food Quality (LNV). The MEB evaluates medicines independently and scientifically.